Treatment of Bipolar Disorders and Metabolic Syndrome:

Implications for Primary Care

Log in or subscribe to view full content.
Article is also available for purchase the article in one of the available formats.
Paul F. Bell, PhD; James P. McKenna, MD; and Brandon M. Roscoe, MD

Table of Contents

Postgraduate Medicine:

Volume 121 No. 5


Clinical Focus

Purchase this article in one of the formats specified below:

DOI: 10.3810/pgm.2009.09.2060
Abstract: Recognition of the prevalence of mood disorders and increased availability of medication options have led to calls for treating bipolar disorders in the primary care setting. Second-generation antipsychotic medications (SGAs) were initially lauded for treating bipolar disorders because of their efficacy and perceived safety relative to first-generation antipsychotic medications. Metabolic syndrome is a constellation of risk factors for cardiovascular disease and type 2 diabetes mellitus, which may emerge when treating bipolar disorders with SGAs. We conducted a search of the research literature examining the association between different SGAs and metabolic syndrome. Based on our review, we offer guidelines for monitoring patient status regarding metabolic syndrome and for providing interventions to promote healthy diet and exercise.

Keywords: bipolar disorders , metabolic syndrome , mood disorders , antipsychotic medication